Accelerating Clinical Trial assessment by Optimised Review
Sector: Hospital • Location: Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Moldova, Montenegro, Netherlands, Portugal, Slovakia, Slovenia, Spain, Sweden, Poland
Source: EU Funding & Tenders Portal
Regulation (EU) 536/2014 on clinical trials on medicinal products for human use (Clinical Trials Regulation, CTR) establishes a harmonised legal framework for the authorisation, conduct and supervision of clinical trials across the EU/EEA. While the CTR and the Clinical Trials Information System (CTIS) have created a single regulatory entry point for clinical trials, experience since the start of
- Status
- Prospective
- Sector
- Hospital, Cement
- Location
- Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Moldova, Montenegro, Netherlands, Portugal, Slovakia, Slovenia, Spain, Sweden, Poland
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Accelerating Clinical Trial assessment by Optimised Review
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Regulation (EU) 536/2014 on clinical trials on medicinal products for human use (Clinical Trials Regulation, CTR) establishes a harmonised legal framework for the authorisation, conduct and supervision of clinical trials across the EU/EEA. While the CTR and the Clinical Trials Information System (CTIS) have created a single regulatory entry point for clinical trials, experience since the start of application has demonstrated that day-to-day implementation remains uneven across Member States. Differences persist in assessment practices, interfaces between Part I and Part II, cooperation between national competent authorities (NCAs) and Medical Research Ethics Committees (MRECs), coordination of timelines, and integration of inspections outcomes. These divergences directly affect the efficiency, predictability and coherence of multinational clinical trial assessments. At the same time, the complexity of clinical trials is increasing. Innovative trial designs, novel therapies (including advanced therapy medicinal products (ATMPs), decentralised and hybrid trial elements, complex statistical methodologies and the growing use of digital and AI-supported tools place additional demands on assessment. These developments require specialised or new expertise, structured cooperation and consistent interpretation of CTR provisions across the EU/EEA. Unequal exposure to complex or innovative trials, limited work-sharing and fragmented access to training and peer exchange further exacerbate capacity differences between Member States, particularly for those where clinical trials are less frequently performed. The relevance and urgency of addressing these implementation challenges are reinforced by the proposed European Biotech Act, which explicitly identifies clinical trials as a critical bottleneck for the Union’s competitiveness in health biotechnology and proposes targeted amendments to the CTR to simplify, streamline and accelerate clinical trial authorisation and conduct. The Biotech Act underlines that, without effective and convergent CTR implementation at national level, broader EU measures to strengthen health biotechnology, support innovation and reduce time to market cannot achieve their intended impact. The proposed amendments are expected to affect assessment timelines, coordination mechanisms, interfaces between NCAs and MRECs, and the handling of innovative trial elements, thereby increasing the operational demands on all actors. Against this background, the Joint Action HS-g-25-27 addresses a clear and well-documented need: to support Member States in the practical, coherent and timely implementation of the CTR, including preparedness for forthcoming amendments introduced by the European Biotech Act. The Joint Action is designed as an implementation- and practice-oriented instrument that enables authorities to anticipate regulatory changes, test and refine assessment approaches in real procedures, and build sustainable capacity across the EU/EEA network. The project is fully aligned with the scope and general objectives of the call, which aims to: • support effective implementation of the CTR, • improve harmonisation and streamlining of clinical trial assessment, • strengthen training and cooperation of assessors, MRECs, and GCP inspectors, • enhance the handling of complex and innovative trials, and • promote onboarding and reliance-based cooperation across the EU/EEA. ACTOR contributes to these priorities by combining operational pilots, structured cooperation models, targeted training, guidance development and twinning mechanisms within a single Joint Action framework. The project focuses on testing and documenting concrete assessment workflows, cooperation interfaces and tools that can be reused by Member States in routine CTR implementation. Particular attention is given to multinational procedures, where inefficiencies and divergences have the greatest impact on timelines and sponsor predictability. Th |
Location
Country | Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Moldova, Montenegro, Netherlands, Portugal, Slovakia, Slovenia, Spain, Sweden, Poland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Cement |
Article published date | 2026-11-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
